Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer

Last updated: March 6, 2017
Sponsor: Vastra Gotaland Region
Overall Status: Completed

Phase

N/A

Condition

Colorectal Cancer

Colon Cancer

Treatment

N/A

Clinical Study ID

NCT03072641
ALFGBG-542821
  • Ages > 18
  • All Genders

Study Summary

The purpose of the study is to determine if probiotic bacteria have a beneficial effect on the colon cancer-associated microbiota and epigenetic alterations in colon cancer. Dietary supplementation consists of two ProBion Clinica tablets, yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • At least one malignant tumor in the colon

Exclusion

Exclusion Criteria:

  • Study subjects with adenomas, or

  • who received recent antibiotic therapy or

  • consumed probiotics regularly were excluded.

Study Design

Total Participants: 20
Study Start date:
June 03, 2010
Estimated Completion Date:
March 31, 2016